Effects of Salvia miltiorrhiza and Radix astragali on the TGF-Î²/Smad/Wnt pathway and the pathological process of liver fibrosis in rats

Cao, Tingting; Lü, Yuan; Zhu, Minwei; Cheng, Jidong; Bai, Ye; Fang, Nanyuan; Cui, Yueping; Xue, Bin; Najafi, Moslem Lari; Kazemi, Elham

doi:10.14715/cmb/2020.66.6.9

Cited by 17 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wnt and its downstream effectors regulate various processes during cancer progression (including tumorigenesis, tumor growth, cellular senescence, and cellular death), differentiation, and metastasis 32 . Some previous studies have reported that there is a cross talk between the Wnt/β‐catenin pathway and TGF‐β/SMAD pathway 33,34 . Interestingly, in the present work, we demonstrated that SMAD2 could positively regulate the expression of WNT1 in BCa cells, and circ_0002623 could regulate WNT1 expression via the miR‐1276/SMAD2 axis.…”

Section: Discussionsupporting

confidence: 54%

“… 32 Some previous studies have reported that there is a cross talk between the Wnt/β‐catenin pathway and TGF‐β/SMAD pathway. 33 , 34 Interestingly, in the present work, we demonstrated that SMAD2 could positively regulate the expression of WNT1 in BCa cells, and circ_0002623 could regulate WNT1 expression via the miR‐1276/SMAD2 axis. However, the detailed mechanism by which SMAD2 regulates WNT1 is still obscure, which requires further investigation.…”

Section: Discussionsupporting

confidence: 47%

See 1 more Smart Citation

Circ_0002623 promotes bladder cancer progression by regulating the miR‐1276/SMAD2 axis

et al. 2022

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are key regulatory factors in the development of multiple cancers. This study is targeted at exploring the effect of circ_0002623 on bladder cancer (BCa) progression and its mechanism. Circ_0002623 was screened out by analyzing the expression profile of circRNAs in BCa tissues. Circ_0002623, miR-1276, and SMAD2 mRNA expression levels in clinical sample tissues and cell lines were detected through quantitative real-time polymerase chain reaction (qRT-PCR). After circ_0002623 had been overexpressed or silenced in BCa cells, the cell proliferation, migration, and cell cycle were evaluated by CCK-8, BrdU, Transwell assay, and flow cytometry. Tumor xenograft model was used to validate the biological function of circ_0002623 in vivo. Bioinformatics analysis and dual-luciferase reporter gene assay were conducted for analyzing and confirming, respectively, the targeted relationship between circ_0002623 and miR-1276, as well as between miR-1276 and SMAD2.The regulatory effects of circ_0002623 and miR-1276 on the expression levels of TGFβ, WNT1, and SMAD2 in BCa cells were detected by Western blot. We reported that, in BCa tissues and cell lines, circ_0002623 was upregulated, whereas miR-1276 was downregulated. Circ_0002623 positively regulated BCa cell proliferation, migration, and cell cycle progression. Additionally, circ_0002623 could competitively bind with miR-1276 to increase the expression of SMAD2, the target gene of miR-1276. Furthermore, circ_0002623 could regulate the expression of TGFβ and WNT1 via modulating miR-1276 and SMAD2. This study helps to better understand the molecular mechanism underlying BCa progression.

show abstract

Section: Discussionsupporting

confidence: 54%

Section: Discussionsupporting

confidence: 47%

Circ_0002623 promotes bladder cancer progression by regulating the miR‐1276/SMAD2 axis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The combination of Astragalus and Salvia miltiorrhiza Bunge is also commonly used in fibrotic diseases. Studies have proven this combination has favorable therapeutic efficacy in hypertrophic scar ( Wu et al, 2014 ), liver fibrosis ( Cao et al, 2020 ), cardiac fibrosis ( Mao et al, 2015 ; Zhang et al, 2021b ), renal fibrosis ( Han et al, 2021 ).…”

Section: Effect Of Astragalus On Fibrotic Diseasesmentioning

confidence: 99%

Astragalus and its formulas as a therapeutic option for fibrotic diseases: Pharmacology and mechanisms

Zhu¹,

Chai

Xiao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Fibrosis is the abnormal deposition of extracellular matrix, characterized by accumulation of collagen and other extracellular matrix components, which causes organ dysfunction and even death. Despite advances in understanding fibrosis pathology and clinical management, there is no treatment for fibrosis that can prevent or reverse it, existing treatment options may lead to diarrhea, nausea, bleeding, anorexia, and liver toxicity. Thus, effective drugs are needed for fibrotic diseases. Traditional Chinese medicine has played a vital role in fibrotic diseases, accumulating evidence has demonstrated that Astragalus (Astragalus mongholicus Bunge) can attenuate multiple fibrotic diseases, which include liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, renal fibrosis, cardiac fibrosis, and so on, mechanisms may be related to inhibition of epithelial-mesenchymal transition (EMT), reactive oxygen species (ROS), transforming growth factor beta 1 (TGF-β1)/Smads, apoptosis, inflammation pathways. The purpose of this review was to summarize the pharmacology and mechanisms of Astragalus in treating fibrotic diseases, the data reviewed demonstrates that Astragalus is a promising anti-fibrotic drug, its main anti-fibrotic components are Calycosin, Astragaloside IV, Astragalus polysaccharides and formononetin. We also review formulas that contain Astragalus with anti-fibrotic effects, in which Astragalus and Salvia miltiorrhiza Bunge, Astragalus and Angelica sinensis (Oliv.) Diels are the most commonly used combinations. We propose that combining active components into new formulations may be a promising way to develop new drugs for fibrosis. Besides, we expect Astragalus to be accepted as a clinically effective method of treating fibrosis.

show abstract

“…In addition to the direct effects of inhibiting the activated HCSs, SM could indirectly enhance the activities of NK cell to reduce liver fibrosis ( Peng et al, 2018 ). Several experimental studies had reported that SM could couple with some herbal medicines, such as radix astragali ( Yang et al, 2008 ; Cao et al, 2020 ), stephania tetrandra ( Chor et al, 2009 ), ligusticum chuanxiong and glycyrrhiza glabra ( Lin et al, 2008 ), to exert the antifibrotic effects via alleviating collagen deposition and reducing inflammation in the liver. Moreover, the active anti-fibrotic ingredients from SM have gained an increasing amount of attention.…”

Section: Pharmacological Actions Of Salvia Miltiorrhiza ...mentioning

confidence: 99%

Salvia miltiorrhiza in thorax and abdomainal organ fibrosis: A review of its pharmacology

Zhao

Ping

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Organ fibrosis is a common pathological change that finally results in organ failure, which involves the destruction of parenchyma cells, the activation of mesenchymal cells and the imbalance of immunological cells. In recent years, although some breakthroughs have been made in understanding the pathogenesis and therapeutics of organ fibrosis, no registered drugs could directly target the fibrotic process, which constitutes a major biomedical challenge. Salvia miltiorrhiza (SM) is a well-known medicinal plant in China, which has been widely applied because of its pharmacological effects on anti-oxidative, anti-myocardial infarction, anti-fibrotic, anti-inflammatory, and anti-neoplastic properties. Accumulated evidence suggested that SM played critical roles against organ fibrosis in vivo and in vitro experiments by its multiple biological compounds. In this review, we discussed the recent advances on the phytochemistry and pharmacological mechanisms of SM and its active ingredients in liver, lung, kidney, and heart fibrosis, which might help to promote the treatment of fibrotic diseases in thorax and abdomainal viscera in clinic.

show abstract

Effects of Salvia miltiorrhiza and Radix astragali on the TGF-Î²/Smad/Wnt pathway and the pathological process of liver fibrosis in rats

Cited by 17 publications

References 34 publications

Circ_0002623 promotes bladder cancer progression by regulating the miR‐1276/SMAD2 axis

Circ_0002623 promotes bladder cancer progression by regulating the miR‐1276/SMAD2 axis

Astragalus and its formulas as a therapeutic option for fibrotic diseases: Pharmacology and mechanisms

Salvia miltiorrhiza in thorax and abdomainal organ fibrosis: A review of its pharmacology

Contact Info

Product

Resources

About